GSTM1 and chronic kidney disease: Furthermore, a statistically significant increased risk of mortality was noted in the high Hb-level group (Relative risk (RR) 1.18; 95% CI, 1.02–1.37) among CKD patients with anemia; however, both the high and low Hb groups were treated with ESAs.